BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32650519)

  • 1. Transitions of Liver and Biliary Enzymes during Proton Beam Therapy for Hepatocellular Carcinoma.
    Sumiya T; Mizumoto M; Oshiro Y; Baba K; Murakami M; Shimizu S; Nakamura M; Hiroshima Y; Ishida T; Iizumi T; Saito T; Numajiri H; Nakai K; Okumura T; Sakurai H
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32650519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do Biliary Complications after Proton Beam Therapy for Perihilar Hepatocellular Carcinoma Matter?
    Yoo GS; Yu JI; Park HC; Hyun D; Jeong WK; Lim HY; Choi MS; Ha SY
    Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32847035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of liver enzymes on living related liver transplantation patients with acute rejection.
    Chiu KW; Chen YS; de Villa VH; Wang CC; Eng HL; Wang SH; Liu PP; Jawan B; Huang TL; Cheng YF; Chen CL
    Hepatogastroenterology; 2005; 52(66):1825-7. PubMed ID: 16334785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leucine amino peptidase a better indicator of carcinoma of liver, biliary tract and pancreas.
    Ghadge MS; Sirsat AV; Bhansali MS; Desouza LJ; Jagannath P
    Indian J Clin Biochem; 2001 Jan; 16(1):60-4. PubMed ID: 23105293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of serum aspartate aminotransferase and gamma-glutamyl transpetidase as biomarkers in hepatotoxicity.
    Robles-Diaz M; Garcia-Cortes M; Medina-Caliz I; Gonzalez-Jimenez A; Gonzalez-Grande R; Navarro JM; Castiella A; Zapata EM; Romero-Gomez M; Blanco S; Soriano G; Hidalgo R; Ortega-Torres M; Clavijo E; Bermudez-Ruiz PM; Lucena MI; Andrade RJ; ;
    Liver Int; 2015 Nov; 35(11):2474-82. PubMed ID: 25809419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of alkaline phosphatase, gamma-glutamyl transpeptidase and lactate dehydrogenase in hepatocellular carcinoma patients treated with liver resection.
    Wu SJ; Lin YX; Ye H; Xiong XZ; Li FY; Cheng NS
    Int J Surg; 2016 Dec; 36(Pt A):143-151. PubMed ID: 27793641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Dose distributions of proton beam therapy for hepatocellular carcinoma: a comparative study of treatment planning with 3D-conformal radiation therapy or intensity-modulated radiation therapy].
    Li JM; Yu JM; Liu SW; Chen Q; Mu XK; Jiang QA; Zhao MH; Zhang JG
    Zhonghua Yi Xue Za Zhi; 2009 Dec; 89(45):3201-6. PubMed ID: 20193534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential liver and bone biochemical changes in hyperthyroidism: prospective controlled follow-up study.
    Huang MJ; Li KL; Wei JS; Wu SS; Fan KD; Liaw YF
    Am J Gastroenterol; 1994 Jul; 89(7):1071-6. PubMed ID: 7912472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The protective role of ellagitannins flavonoids pretreatment against N-nitrosodiethylamine induced-hepatocellular carcinoma.
    Hussein RH; Khalifa FK
    Saudi J Biol Sci; 2014 Dec; 21(6):589-96. PubMed ID: 25473368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility of dynamic adaptive passive scattering proton therapy with computed tomography image guidance in the lung.
    Moriya S; Tachibana H; Hotta K; Nakamura N; Sakae T; Akimoto T
    Med Phys; 2017 Sep; 44(9):4474-4481. PubMed ID: 28665491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial clinical outcomes of proton beam radiotherapy for hepatocellular carcinoma.
    Yu JI; Yoo GS; Cho S; Jung SH; Han Y; Park S; Lee B; Kang W; Sinn DH; Paik YH; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Park HC
    Radiat Oncol J; 2018 Mar; 36(1):25-34. PubMed ID: 29580046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three cases of hepatocellular carcinoma treated 4 times with proton beams.
    Murakami M; Fukumitsu N; Okumura T; Numajiri H; Murofushi K; Ohnishi K; Mizumoto M; Ishikawa H; Tsuboi K; Sakurai H
    Mol Clin Oncol; 2020 Jan; 12(1):31-35. PubMed ID: 31814974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I dose-escalation study of proton beam therapy for inoperable hepatocellular carcinoma.
    Kim TH; Park JW; Kim YJ; Kim BH; Woo SM; Moon SH; Kim SS; Koh YH; Lee WJ; Park SJ; Kim JY; Kim DY; Kim CM
    Cancer Res Treat; 2015 Jan; 47(1):34-45. PubMed ID: 25381830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing alcohol intake & its dose-dependent effects on liver enzymes by 24-h recall and questionnaire using NHANES 2001-2010 data.
    Agarwal S; Fulgoni VL; Lieberman HR
    Nutr J; 2016 Jun; 15(1):62. PubMed ID: 27334005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dynamic change study of dermatitis medicamentosa-like of trichloroethylene patients with liver damage].
    Liu W; Zhang YF; Zhang ZM; Li PM; Jiang XD; Zhou GF; Liu JJ
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2011 Oct; 29(10):790-3. PubMed ID: 22468317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic resection of hepatocellular carcinoma after proton beam therapy: A case report.
    Kinjo N; Ikeda Y; Taguchi K; Sugimoto R; Maehara S; Tsujita E; Kawano H; Yamaguchi S; Egashira A; Minami K; Yamamoto M; Morita M; Toh Y; Okamura T
    Hepatol Res; 2016 Mar; 46(5):483-8. PubMed ID: 26286377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum liver function profiles in coking workers.
    Wu MT; Mao IF; Wypij D; Ho CK; Chen JR; Christiani DC
    Am J Ind Med; 1997 Nov; 32(5):478-86. PubMed ID: 9327071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of Radiation-Induced Liver Disease in Eastern and Western Patients With Hepatocellular Carcinoma Undergoing Proton Beam Therapy.
    Hsieh CE; Venkatesulu BP; Lee CH; Hung SP; Wong PF; Aithala SP; Kim BK; Rao A; Tung-Chieh Chang J; Tsang NM; Wang CC; Lee CC; Lin CC; Tseng JH; Chou WC; Wang YC; Krishnan S; Hong JH
    Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):73-86. PubMed ID: 30797890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Withholding parenteral nutrition during critical illness increases plasma bilirubin but lowers the incidence of biliary sludge.
    Vanwijngaerden YM; Langouche L; Brunner R; Debaveye Y; Gielen M; Casaer M; Liddle C; Coulter S; Wouters PJ; Wilmer A; Van den Berghe G; Mesotten D
    Hepatology; 2014 Jul; 60(1):202-10. PubMed ID: 24213952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of liver function tests in hepatocellular carcinoma.
    Lopez JB; Balasegaram M; Thambyrajah V; Timor J
    Malays J Pathol; 1996 Dec; 18(2):95-9. PubMed ID: 10879229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.